Solvay Pharma Россия и СНГ Обратная связь Карта сайта
Понедельник, 23 марта 2009 г.
Уже зарегистрировались 56308 пользователей
В стремлении к прогрессу, с заботой о людях
Феварин
Регистрация

Библиография

Включен в программу ОНЛС

  1. Leonard BE. Pharmacological differences of serotonin reuptake inhibitors and possible clinical relevance. Drugs 1992; 43 (Suppl2): 3-10.
  2. Hyttel J. Comparative pharmacology of selective serotonin reuptake inhibitors (SSRIs). Nordisk Journal of Psychiatry 1993; 47 (SuppI 30): 5-12.
  3. Tollefson GD. Antidepressant treatment and side effect consideration. Journal of Clinical Psychiatry 1991; 52 (SuppI): 4-13.
  4. Olivier В, Bosch L, van Hest A et al. Preclinical evidence on the psychotropic profile of fluvoxamine. Pharmacopsychiatry 1993; 26 (SuppI): 2-9.
  5. Woods A, Smith C, Szewczak M et al. Selective serotonin reuptake inhibitors decrease schedule-induced polydipsia in rats: a potential model for obsessive-compulsive disorder. Psychopharmacology 1993; 112: 195-198.
  6. Schreiber S, Backer MM, Yanai J et al. The antinociceptive effect of fluvoxamine. European Neuropsychopharmacology 1996; 6: 281-284.
  7. Dirksen R, Van Luijtelaar EL, Van Rijn CM. Selective serotonin reuptake inhibitors may enhance responses to noxious stimulation. Pharmacology, Biochemistry and Behavior 1998; 60: 719-725.
  8. Kulin NA, Pastuszak A, Sage SR et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study JAMA 1998; 279: 1873.
  9. Hindmarch I. The behavioural toxicity of antidepressants: effects on cognition and sexual dysfunction. International Clinical Psychopharmacology 1998; 13 (SuppI б): 5-8.
  10. Hindmarch I. The behavioural toxicity of the selective serotonin reuptake inhibitors. International Clinical Psychopharmacology 1995; 9 (SuppI 4): 13-17.
  11. Fairweather DB, Ashford J, Hindmarch I. Effects of fluvoxamine and dothiepin on psychomotor abilities in healthy volunteers. Pharmacology, Biochemistry and Behavior 1996; 53: 265-269.
  12. Weinstein A, Wilson S, Bailey J, Mutt DJ. Antidepressants actions on peripheral visual detection mechanisms in humans. Journal of Psychopharmacology 1995; 9(Suppl): Abs149, A38.
  13. Curran HV, Lader M. The psychopharmacological effects of repeated doses of fluvoxamine, mianserin and placebo in healthy human subjects. European Journal of Clinical Pharmacology 1986; 29: 601-607.
  14. Moon CAL, Jesinger DK. The effects of psychomotor performance of fluvoxamine versus mianserin in depressed patients in general practice. British Journal of Clinical Practice 1991; 45: 259-262.
  15. Saletu B. Pharmaco-EEG profiles of antidepressants. Pharmacodynamic studies with fluvoxamine. British Journal of Clinical Pharmacology 1983; 15 (SuppI 3): 369S-384S.
  16. Van Marten J. Overview of the pharmacokinetics of fluvoxamine. Clinical Pharmacokinetics 1995; 29 (SuppI 1): 1-9.
  17. Van Harten J, van Bemmel P, Dobrinska MR et al. Bioavailability of fluvoxamine given with and without food. Biopharmaceutics and Drug Disposition 1991; 12: 571-576.
  18. Overmars H, Scherpenisse PM, Post LC. Fluvoxamine maleate: metabolism in man. European Journal of Drug Metabolism and Pharmacokinetics 1983; 8: 269-280.
  19. Hrdina PD. Pharmacology of serotonin uptake inhibitors: focus on fluvoxamine. Journal of Psychiatric Neuroscience 1991; 16 (SuppI 1): 10-18.
  20. Wright S, Dawling S, Ashford JJ. Excretion of fluvoxamine in breast milk. British Journal of Clinical Pharmacology 1991; 31:209.
  21. Van Harten J, Duchier J, Devissaguet J-P et al. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. Clinical Pharmacokinetics 1993; 24: 177-182.
  22. Wilde Ml, PloskerGL, Benfield P. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993; 46: 895-924.
  23. De Vries MH, Raghoebar M, Mathlener IS et al. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Therapeutic Drug Monitoring 1991; 14: 493-498.
  24. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clinical Pharmacokinetics 1996; 31: 444-469.
  25. DeVane CL, Gill HS. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. Journal of Clinical Psychiatry 1997; 58 (SuppI 5): 7-14.
  26. DeVane CL. Translational pharmacokinetics: current issues with newer antidepressants. Depression and Anxiety 1998; 8 (SuppI 1): 64-70.
  27. Wagner W, Vause EW. Fluvoxamine. A review of global drug-drug interaction data. Clinical Pharmacokinetics 1995; 29 (SuppI 1): 26-32.
  28. Pastrakuljic A, Tang BK, Roberts EA, Kalow W. Distinction of CYP1A1 and CYP1A2 activity by selective inhibition using fluvoxamine and isosafrole. Biochemical Pharmacology 1997:53:531-538.
  29. XuZH,XieHG,Zhou HH. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. British Journal of Clinical Pharmacology 1996; 42: 518-521.
  30. Jeppesen U, Gram LF, Vistisen К et al. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. European Journal of Clinical Pharmacology 1996; 51: 73-78.
  31. Nemeroff CB, DeVane CL, Pollock. BG. Newer antidepressants and the cytochrome P450 system. American Journal of Psychiatry 1996; 153: 1655-1657.
  32. Cialdella E. Fluvoxamine in the management of depressive patients. Gazette Medicale 1991; 98: 43-47.
  33. Martin AJ, Tebbs VM, Ashford JJ. Affective disorders in general practice. Treatment of 6000 patients with fluvoxamine. Pharmatherapeutica 1987; 5: 40-49.
  34. Conti L, Dell'osso L, Re F et al. Fluvoxamine maleate: double-blind clinical trial vs. placebo in hospitalised depressed patients. Current Therapeutic Research 1988; 43: 468-480.
  35. Porro V, Fiorenzoni S, Menga С et al. Single-blind comparison of the efficacy of fluvoxamine versus placebo in patients with depressive syndrome. Current Therapeutic Research 1988; 43: 621-629.
  36. Walczak DD, Apter JT, Halikas JA et al. The oral dose-effect relationship for fluvoxamine: a fixed-dose comparison against placebo in depressed outpatients. Annals of Clinical Psychiatry 1996; 8: 139-151.
  37. Guelfi JD, Dreyfus JF, Pichot P, et al. A double-blind controlled clinical trial comparing fluvoxamine with imipramine. British Journal of Clinical Pharmacology 1983; 15: 411S-417S.
  38. Fabre L, Birkhimer U, Zaborny BA et al, Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. International Clinical Psychopharmacology 1996; 11: 119-127.
  39. Guelfi JD, Dreyfus JF, Pichot P et al. Fluvoxamine and impramine: results of a long-term controlled trial. International Clinical Psychopharmacology 1987; 2: 103-109.
  40. Amin MM, Ananth JV, Coleman BS et al. Fluvoxamine: antidepressant effects confirmed in a placebo-controlled international study. Clinical Neuropharmacology 1984; 7: 580.
  41. Lapierre YD, Browne M, Horn E, et al. Treatment of major affective disorder with fluvoxamine. Journal of Clinical Psychiatry 1987; 48: 65-68.
  42. March JS, Kobak KA, Jefferson JW, et al. A double-blind, placebo-controlled trial of fluvoxamine versus imipramine in outpatients with major depression. Journal of Clinical Psychiatry 1990; 51: 200-202.
  43. Claghorn JL, Earl CQ, Walczak DD, et al. Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients. Journal of Clinical Psychopharmacology 1996; 16: 113-120.
  44. Fabre L, Birkhimer U, Zaborny BA, et al. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients. ' International Clinical Psychopharmacology 1996; 11: 119-127.
  45. Amore M, Bellini M, Berardi D et al. Double-blind comparison of fluvoxamine and imipramine in depressed patients. Current Therapeutic Research 1989; 46: 815-820.
  46. Dominguez RA, Goldstein BJ, Jacobson AF et al. A double-blind placebo-controlled study of fluvoxamine and imipramine in depression. Journal of Clinical Psychiatry 1985; 46: 84-87.
  47. Feighner J, Boyer WF, Meredith Ch, Hendrickson GG. A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression. International Clinical Psychopharmacology 1989; 4: 239-244.
  48. Guy W, Wilson WH, Ban ТА et al. A double-blind clinical trial of fluvoxamine and imipramine in patients with primary depression. Drug Development Research 1984; 4: 143-153.
  49. Itil TM, Shrivastava RK, Mukherjee S et al. A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression. British Journal of Clinical Pharmacology 1983; 15 (SuppI 3): 433-438.
  50. Norton KRW, Sireling LI, Bhat AV et al. A double-blind comparison of fluvoxamine, imipramine and placebo in depressed patients. Journal of Affective Disorders 1984; 7:297-232.



Solvay Pharma
Баннерная сеть Солвей-Фарма.ру
Адрес


Последнее обновление  23.03.2009 г.